Drugs / SC-102
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06710158 | Dec 2024 → Dec 2026 expected | high grade malignant neoplasm | Tianjin ConjuStar Biologics Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-06-04 | Tianjin ConjuStar Biologics Co., Ltd. | Regulatory EphA2 targeting PDC drug SC-102 received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) conjustar.com ↗
On May 30, 2025, Conjustar Biologics announced that it's EphA2 targeting PDC drug SC-102 has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) for evaluating the safety and efficacy of SC-102 in patients with advanced or metastatic solid tumors expressing EphA2. |
| 2024-09-02 | Tianjin ConjuStar Biologics Co., Ltd. | Regulatory Investigational new drug (IND) application of SC-102 was approved by CDE of NMPA conjustar.com ↗
On August 8, 2024, Conjustar Biologics announced that the investigational new drug (IND) application for the company's second peptide-drug conjugate (PDC), SC-102 for Injection, for the treatment of advanced malignant solid tumors expressing EphA2, was approved by the Center for Drug Evaluation (CDE) of the Chinese National Medical Products Administration. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-06-04 | Tianjin ConjuStar Biologics Co., Ltd. | EphA2 targeting PDC drug SC-102 received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) conjustar.com ↗ |
| 2024-12-26 | Tianjin ConjuStar Biologics Co., Ltd. | Key Milestone | Completion of the first patient enrolled in the phase I study of the PDC SC-102 conjustar.com ↗ |
| 2024-09-02 | Tianjin ConjuStar Biologics Co., Ltd. | Investigational new drug (IND) application of SC-102 was approved by CDE of NMPA conjustar.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SC-102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06710158 ↗ |
| Action | Inhibit | “a tubulin inhibitor” NCT06710158 ↗ |
| Modality | Peptide | “SC-102 is a peptide drug conjugate (PDC)” NCT06710158 ↗ |
| Target | EPHA2 | “an EphA2-targeting peptide” NCT06710158 ↗ |